ERR2208915
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- COMPLEMENT+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- COAGULATION+0.300
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- MYOGENESIS-0.300
- NOTCH_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ANGIOGENESIS-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- ADIPOGENESIS-0.100
- APICAL_JUNCTION-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943003 | — | — | 0.887 |
| 2 | SRR975600 | — | — | 0.885 |
| 3 | SRR8518244 | — | D | 0.857 |
| 4 | TCGA-AO-A128-01A-11R-A10J-07 | — | D | 0.849 |
| 5 | TCGA-AR-A1AT-01A-11R-A12P-07 | — | C | 0.844 |
| 6 | C3L-04757 | — | cohortA1 | 0.844 |
| 7 | MNG766 | — | — | 0.836 |
| 8 | b4fd9abd-cb2a-4d1b-abb2-8e2796d009cc | — | — | 0.827 |
| 9 | TCGA-CR-6478-01A-11R-1873-07 | — | — | 0.826 |
| 10 | SRR12696798 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |